GlassScriptPhysician profile
Keith A Schorn
NPI 1659386944
$3,739.24
in general payments reported to CMS, 2019-2025
40 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $210 · 2021: $640 · 2022: $475 · 2023: $511 · 2024: $1,137 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $736.08 | 2021-2025 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.43 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $351.30 | 2019-2024 | Shingrix, Bexsero, Arexvy |
| Merck Sharp & Dohme LLC | $230.04 | 2020-2025 | Gardasil 9, Vaxelis, Proquad |
| Abbvie INC. | $186.79 | 2021-2024 | Ubrelvy |
| Sanofi Pasteur INC. | $159.48 | 2021-2025 | |
| Novo Nordisk INC | $157.69 | 2019-2025 | Ozempic, Rybelsus |
| Genentech USA, INC. | $152.38 | 2019-2022 | |
| Pfizer INC. | $131.50 | 2023-2025 | |
| Lilly USA, LLC | $125.31 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Cranial Technologies, INC | $94.81 | 2019-2025 | Doc Band |
| Astellas Pharma US INC | $92.15 | 2019-2024 | Veozah |
| Allergan, INC. | $87.00 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $82.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.45 | 2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $60.90 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $43.51 | 2021 | |
| Alk-Abello, INC | $39.09 | 2025 | Neffy, Odactra, Grastek |
| Amgen INC. | $38.78 | 2019 | |
| Inspire Medical Systems, INC. | $38.57 | 2024-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $35.73 | 2023-2024 | Flumist Quadrivalent, Airsupra |
| Antares Pharma, INC. | $33.37 | 2021 | |
| Dynavax Technologies Corporation | $32.75 | 2022-2024 | Heplisav-B |
| Medtronic, INC. | $31.58 | 2023 | Venaseal |
| Dexcom, INC. | $31.12 | 2022-2023 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $29.05 | 2022-2023 | Quviviq |
| Corium, LLC | $29.04 | 2025 | Azstarys |
| Kaleo, INC. | $28.91 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.16 | 2023 | |
| Acella Pharmaceuticals, LLC | $26.06 | 2023 | NP Thyroid 60 |
| Ironshore Pharmaceuticals INC. | $22.67 | 2023 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $22.40 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.39 | 2024 | Gvoke Hypopen |
| Abbott Laboratories | $19.95 | 2021 | |
| Ethicon US, LLC | $19.74 | 2019 | |
| Eisai INC. | $18.71 | 2021 | |
| Esperion Therapeutics, INC. | $17.84 | 2021 | |
| Seqirus USA INC | $12.75 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Teva Pharmaceuticals USA, INC. | $12.12 | 2019 | |
| Vistapharm, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Schorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.